-
Promising COVID-19 Therapeutics(Post)
SARS-CoV-2, the causative viral agent of the novel coronavirus disease COVID-19, has sparked a global effort for creating prophylactic and therapeutic interventions. The following
Inhibiting cell division(Post)Unregulated cell growthCancer, although heterogeneous by its very nature, can be broadly defined as a set of diseases characterised by unregulated cell growth leading to invasion of surrounding
Eosinophils, IL-5 and the Type 2 Granulocyte Axis(Page) No Ligand, No Kinase, No Problem(Post)HER2 has no ligand. HER3 has no kinase. Together they are the most potent signalling pair in human biology. That single sentence explains most of what is strange about this receptor family and all of
Hijacking the Skull's Gateways: A New 'Backdoor' for Brain Drug Delivery(Post)For decades, the brain has been considered an immune sanctuary, protected by the formidable blood-brain barrier. This intricate defense system, while vital for safeguarding our most complex organ, ha
Codrituzumab: Unveiling Its Role in Cancer Research and Treatment(Post)What You Need to Know About CodrituzumabWhat is Codrituzumab?Codrituzumab is an investigational monoclonal antibody targeting CD47, an immune checkpoint that regulates immune responses i
Tertiary Lymphoid Structures: The Body's Hidden Arsenals in the Fight Against Cancer(Post)Tertiary Lymphoid Structures: The Body's Hidden Arsenals in the Fight Against Cancer Imagine a battlefield within the body, where the immune system stands as the last line of defense against the rele
TLR Innate Sensing Pathway: Receptors, MyD88/TRIF and Assays(Post)Toll-like receptors are the reason a milligram of endotoxin can kill a mouse. They are the fastest, least discriminating layer of immunity: germline-encoded sensors that read conserved microbial chem
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Types of Glial Cells(Post)Microglia Astrocytes Oligodendrocytes Glial
Citrullination, NETs and Rheumatoid Arthritis(Page) Mouse Monoclonal Antibody(Post)Mouse monoclonal antibodies are a valuable tool in the biomedical field. They can be used for a variety of applications, from research to clinical diagnostics. In this blog post, we will di
Understanding the mTOR Signaling Pathway: A Key Player in Cell Growth and Metabolism(Post)Cell Signalling · MetabolismThe mTOR Signalling PathwaymTOR is a master regulator of cell growth, metabolism and survival, integrating nutrient, growth-factor and energy signals through two comp
The Intestinal Barrier: Junctions, Mucus and Permeability(Page) Erk Signal Transduction Explained: Step-by-Step Process & Key Concepts(Post)The ERK signal transduction pathway stands as a fundamental mechanism in cellular biology, orchestrating a wide array of physiological processes, including cell division, differentiation, and surv
The Adenosine Axis: How CD39 and CD73 Switch Immunity Off(Post)The most abundant immunosuppressive molecule in a solid tumour is not a protein. It is adenosine — a metabolite, produced from ATP in two enzymatic steps, at concentrations orders of magnitude above
SLAMF7: Activating Natural Killer Cells for Potent Anti-Cancer Responses(Post)Introduction to SLAMF7 in Cancer Immunotherapy SLAMF7, also known as Signaling Lymphocytic Activation Molecule F7, is a surface receptor found on natural killer (NK) cells, T cells, plasm
Carbon Dioxide sensing in Immune Cells(Post)BRIEF HISTORY OF THE “GREEN” EVOLUTION OF OXYGEN AND CARBON DIOXIDE WITHIN OUR ATMOSPHERE Million years ago carbon dioxide (CO2) levels used to be conside
CD31: A Comprehensive Look at an Essential Biomarker(Post)What is CD31? CD31, also known as PECAM-1, was originally described as a cell surface antigen present on platelets and megakaryocytes. CD31 is
No Cytokine on This Pathway Touches Bone(Post)Not one immune cytokine on this pathway touches bone. TNF, IL-1β, IL-6 and IL-17A all act on osteoblasts, osteocytes and synovial fibroblasts, and it is those stromal cells that decide between RANKL